| Identification | More | [Name]
Droloxifene | [CAS]
82413-20-5 | [Synonyms]
3-[1-[4-(2-dimethylaminoethoxy)phenyl]-2-phenyl-but-1-enyl]phenol
DROLOXIFENE
DROLOXIFENE CITRATE
(E)-3-[1-[4-[2-(DIMETHYLAMINO)ETHOXY]PHENYL]-2-PHENYL-1-BUTENYL]-PHENOL CITRATE
TAMOXIFEN, 3-HYDROXY-, CITRATE, (E)-
(e)-1-(4’-(2-dimethylaminoethoxy)phenyl)-1-(3’-hydroxyphenyl)-2-phenylbut-1-
(e)-3-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenyl-1-butenyl)phenol
(e)-alpha-(para-(2-(dimethylamino)ethoxy)phenyl)-alpha’-ethyl-3-stilbenol
3-hydroxytamoxifen
e-droloxifene
k060
k060e
k21060e
trans-1-(4-beta-dimethylaminoethoxyphenyl)-1-(3-hydroxyphenyl)-2-phenylbut-1
3-[(1E)-1-[4-[2-(Dimethylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]-phenol
K 21.060
(E)-α-[p-[2-(Dimethylamino)ethoxy]phenyl]-β-ethylstilben-3-ol | [Molecular Formula]
C32H37NO9 | [MDL Number]
MFCD00468089 | [Molecular Weight]
579.64 | [MOL File]
82413-20-5.mol |
| Chemical Properties | Back Directory | [Appearance]
Off-White to Pale-Beige Solid | [Melting point ]
127-129°C | [storage temp. ]
Amber Vial, -20°C Freezer | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [color ]
White to Pale Beige | [Usage]
A Tamoxifen derivative with antitumor effect on estrogen-dependent breast cancer cells | [Stability:]
Light Sensitive | [CAS DataBase Reference]
82413-20-5(CAS DataBase Reference) | [IARC]
3 (Vol. 66) 1996 |
| Hazard Information | Back Directory | [Chemical Properties]
Off-White to Pale-Beige Solid | [Uses]
A Tamoxifen (T006000) derivative with antitumor effect on estrogen-dependent breast cancer cells. | [Uses]
A Tamoxifen derivative with antitumor effect on estrogen-dependent breast cancer cells | [Uses]
anti-estrogen, anti-hyperlipoproteinemic, reduces bone loss | [Definition]
ChEBI: Droloxifene is a stilbenoid. | [in vivo]
Droloxifene (5-20 mg/kg; p.o.; daily for 4 weeks) increases BMD of DFM at 10mg/kg, and completely prevents the decrease of BMC and BMD of DFM induced by ovariectomized (OVX) at 20 mg/kg/day[3]. | Animal Model: | 5-month-old sham-operate rats[3] | | Dosage: | 5, 10, 20 mg/kg | | Administration: | Oral; daily for 4 weeks | | Result: | BMD of DFM increased significantly at 10mg/kg; completely prevented the decrease of BMC and BMD of DFM induced by OVX at 20 mg/kg/day.
|
| [storage]
Store at -20°C |
|
|